Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors

Next Previous
Trial Profile

Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Vorolanib (Primary)
  • Indications Carcinoma; Malignant thymoma; Non-small cell lung cancer; Small cell lung cancer; Thoracic neoplasms
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 10 Sep 2019 Results (n=10) assessing tolerability of Nivolumab and Vorolanib in patients with refractory thoracic tumors, presented at the 20th World Conference on Lung Cancer.
    • 03 Apr 2019 Clinical study design was presented at the 110th Annual Meeting of the American Association for Cancer Research.
    • 25 Mar 2019 Planned number of patients changed from 140 to 177.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top